Back to Search Start Over

Age-specific vaccination coverage estimates for influenza, human papillomavirus and measles containing vaccines from seven population-based healthcare databases from four EU countries – The ADVANCE project

Authors :
Braeye, T. (Toon)
Emborg, H.-D. (Hanne-Dorthe)
Llorente-García, A. (Ana)
Huerta, C. (Consuelo)
Martín-Merino, E. (Elisa)
Duarte-Salles, T. (Talita)
Danieli, G. (Giorgia)
Tramontan, L. (Lara)
Weibel, D.M. (Daniel)
McGee, C. (Chris)
Villa, M. (Marco)
Gini, R. (Rosa)
Lehtinen, M. (Matti)
Titievsky, L. (Lina)
Sturkenboom, M.C.J.M. (Miriam)
Braeye, T. (Toon)
Emborg, H.-D. (Hanne-Dorthe)
Llorente-García, A. (Ana)
Huerta, C. (Consuelo)
Martín-Merino, E. (Elisa)
Duarte-Salles, T. (Talita)
Danieli, G. (Giorgia)
Tramontan, L. (Lara)
Weibel, D.M. (Daniel)
McGee, C. (Chris)
Villa, M. (Marco)
Gini, R. (Rosa)
Lehtinen, M. (Matti)
Titievsky, L. (Lina)
Sturkenboom, M.C.J.M. (Miriam)
Publication Year :
2020

Abstract

Background: The Accelerated Development of VAccine beNefit-risk Collaboration in Europe (ADVANCE) is a public–private collaboration aiming to develop and test a system for rapid benefit-risk monitoring of vaccines using existing healthcare databases in Europe. We estimated vaccine coverage from electronic healthcare databases as part of a fit-for-purpose assessment for vaccine benefit-risk studies. Methods: A retrospective dynamic cohort study was conducted through a distributed network approach. Coverage with measles-vaccine for birth year 2006, human papillomavirus (HPV)-vaccine for birth years 1990–2000 and influenza-vaccine for birth years 1920–1950 was estimated using period-prevalence and inverse probability weighting methods. Seven databases from four countries participated: Italy (Pedianet, Val Padana), Spain (BIFAP, SIDIAP), UK (RCGP-RSC, THIN), Denmark (SSI/AUH). Database access providers extracted the data, transformed it into a common structure and ran an R-script locally. The created output tables were shared and pooled at a central server. Results: The total study population comprised 274,616 persons for measles-vaccine, 2,011,666 persons for HPV-vaccine and 14,904,033 persons for influenza-vaccine. Measles-vaccine coverage varied from 84.3% (Denmark) to 96.5% (Italy, Val Padana) for the first dose and from 82.8% (Italy, Val Padana) to 90.9% (UK) for the second dose at the age of 7 years. The HPV-vaccine coverage, aggregated over birth years 1997–2000, ranged from 60% (UK) to 88.3% (Denmark) at the age of 15 years. The influenza-vaccine coverage for the influenza seasons from 2009 to 2015 for persons aged 65 years and more was roughly stable around 43% in Denmark and around 68% in the UK while a decrease from 58 to 50% was observed in Catalonia (Spain). Conclusions: We obtained detailed, age-specific coverage estimates though a common procedure. We discussed between database comparability and comparability to published national estimates.

Details

Database :
OAIster
Notes :
application/pdf, Vaccine, English
Publication Type :
Electronic Resource
Accession number :
edsoai.on1148971594
Document Type :
Electronic Resource
Full Text :
https://doi.org/10.1016.j.vaccine.2020.02.082